Cinctive Capital Management’s Gilead Sciences GILD Stock Holding History

Cinctive Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,420	Closed	-$1.93M	–	442
2025 Q2	$1.93M	Buy	17,420 +4,218	+32%	+$449K	0.1%	220
2025 Q1	$1.48M	Sell	13,202 -92,520	-88%	-$9.55M	0.11%	185
2024 Q4	$9.77M	Sell	105,722 -79,673	-43%	-$7.17M	0.5%	57
2024 Q3	$15.5M	Buy	+185,395	New	+$14.1M	0.85%	24
2022 Q3	–	Sell	-63,520	Closed	-$3.93M	–	515
2022 Q2	$3.93M	Buy	+63,520	New	+$3.93M	0.16%	205
2021 Q3	–	Sell	-201,779	Closed	-$13.9M	–	588
2021 Q2	$13.9M	Buy	+201,779	New	+$13.5M	0.65%	20
2020 Q1	–	Sell	-136,800	Closed	-$8.89M	–	232
2019 Q4	$8.89M	Buy	+136,800	New	+$8.91M	0.93%	19

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cinctive Capital Management's GILD Position: Q3 2025 in Review

Cinctive Capital Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 17,420 shares — an estimated $1.93M sold.

Cinctive Capital Management first reported a position in GILD in Q4 2019 and held it in 7 quarters. The position peaked at $15.5M in Q3 2024. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

Cinctive Capital Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
Cinctive Capital Management sold 17,420 Gilead Sciences shares in Q3 2025, an estimated $1.93M.
Cinctive Capital Management first reported a position in Gilead Sciences in Q4 2019 and held it in 7 quarters.
Cinctive Capital Management's Gilead Sciences position peaked at $15.5M in Q3 2024.
2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.